CAJ | 학술논문

目的：探讨免疫组织化学法在乳腺癌鉴别诊断中的临床意义，为临床诊断鉴别提供参考。方法对江油市人民医院病理科2006年1月至2013年9月收治的852例浸润性乳腺癌组织标本进行链霉菌抗生物素蛋白-过氧化物酶连结法检测。结果孕激素受体（ PR）阳性率在低年龄组（58．77％）、肿瘤T≤2 cm（60％）、临床分期早较高且差异均具有统计学意义（P＜0．05）；肿瘤 T≤2 cm，雌激素受体（ER）阳性率（68．35％）显著高于其他肿瘤大小组（P ＜0．01），不同年龄、临床分期的阳性率差异无统计学意义（P＞0．05），C-erbB-2在肿瘤大小、临床分期的阳性率差异均具有统计学意义（P＜0．05）；血管内皮生长因子、p53和Ki-67在不同年龄组、肿瘤体积组、临床分期的阳性率差异均无统计学意义（均P＞0．05）。结论免疫组织化学指标中PR、ER、C-erbB-2在乳腺癌鉴别诊断中具有重要指导意义，可用于临床上鉴别诊断乳腺癌。
목적：탐토면역조직화학법재유선암감별진단중적림상의의，위림상진단감별제공삼고。방법대강유시인민의원병이과2006년1월지2013년9월수치적852례침윤성유선암조직표본진행련매균항생물소단백-과양화물매련결법검측。결과잉격소수체（ PR）양성솔재저년령조（58．77％）、종류T≤2 cm（60％）、림상분기조교고차차이균구유통계학의의（P＜0．05）；종류 T≤2 cm，자격소수체（ER）양성솔（68．35％）현저고우기타종류대소조（P ＜0．01），불동년령、림상분기적양성솔차이무통계학의의（P＞0．05），C-erbB-2재종류대소、림상분기적양성솔차이균구유통계학의의（P＜0．05）；혈관내피생장인자、p53화Ki-67재불동년령조、종류체적조、림상분기적양성솔차이균무통계학의의（균P＞0．05）。결론면역조직화학지표중PR、ER、C-erbB-2재유선암감별진단중구유중요지도의의，가용우림상상감별진단유선암。
Objective To investigate the clinical significance of immunohistochemistry in the differential diagnosis of breast cancer,and provide reference for clinical differential diagnosis.Methods 852 cases of Jiangyou City People′s Hospital of January 2006 to September 2013 admitted to the invasion of invasive breast cancer tissue specimens were immunohistochemical staining Streptavidin-Perosidase (the SP) assay. Results PR-positive rate (please give the following corresponding positive rate) in the lower age group(58. 77%),tumor size ≤2 cm(60%),clinical stage early high and the differences were statistically significant (P<0.05);tumor T ≤2 cm,ER-positive rate (68.35%) was significantly higher than other tumors large group (P<0.01),age,clinical stage positive rate difference was not statistically significant(all P>0.05);C-erbB-2 in tumor size,clinical stage positive rate differences are statistically significant(P<0.05);VEGF, p53 and Ki-67 in different age group,tumor volume,positive rate of clinical stage was no significant differ-ence(P>0.05).Conclusion PR,ER,C-erbB-2 of Immunohistochemistry index have an important signifi-cance in differential diagnosis of breast cancer and can be used in clinical differential diagnosis of breast cancer.